TitleProduct

Adalimumab

  • Price:

    Negotiable

  • minimum:

  • Total supply:

  • Delivery term:

    The date of payment from buyers deliver within days

  • seat:

    Shanghai

  • Validity to:

    Long-term effective

  • Last update:

    2018-11-16 04:17

  • Browse the number:

    374

Send an inquiries
+
Shanghai TheraMabs Bio-Technology Co.,Ltd
Contactaixin:

saimai2018(Mr.)  

Email:

sales@theramabs.com

telephone:

+86-21-58582603

phone:

13611999090

Arrea:

Shanghai

Address:

Room 156, 133# Dongzheng Road, Pudong Disrict, Shanghai, China

Website:

http://www.therapeuticmab.com/ http://saimai2018.chinamerchants-logistics.com/

+

Our product is the biosimilar of Adalimumab (331731-18-1), which is recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor with human derived heavy and light chain variable regions and human IgG1: k constant regions. It consists of 1330 amino acids and has a molecular weight of approximately 148 kDa. It is produced by recombinant DNA technology in Chinese Hamster Ovary cell expression system and is purified by a process that includes specific viral inactivation and removal steps.


Features and Advantages:

Name

Biosimilar of Adalimumab

CAS NO.

331731-18-1

Type

Whole antibody

Source

Human

Target

TNF alpha

Clone

Monoclone

Formula

C6428H9912N1694O1987S46

Molecular Weight

148 kDa

Antibody Form

Purified immunoglobulin

Physical Form

Solution

Place of Origin

China (Mainland)

Storage

Sealed and stored at -70±15℃, away from light.


Specifications:

The Biosimilar of Adalimumab is supplied at a concentration of 50 mg/mL; Besides, customized requirement is available. 

Minimum order quantity is 1gram, Annual supply can reach 120kg.


Applications:

Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. 

The Biosimilar of Adalimumab can be used for pre-clinical scientific research and drug registration applications, but cannot be used for human trials or those prohibited by local regulations before approval by drug regulatory authorities.

http://www.therapeuticmab.com/